Scientists hunt for genes behind NF1 skin tumors

NCT ID NCT04941027

Completed Knowledge-focused Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study at Stanford University looked at the DNA of over 1,000 adults with Neurofibromatosis Type 1 (NF1) to find genetic differences that might explain why some people develop more skin neurofibromas than others. Participants provided blood or saliva samples for genetic analysis. The goal was to build a biobank to better understand the disease and eventually personalize care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could help doctors better predict and manage neurofibroma development in people with NF1, leading to more personalized care.
What could go wrong: This is an observational genetic study, not a treatment trial. It may not directly change patient care, and findings may not apply to all NF1 patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neurofibromatosis type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROFIBROMATOSIS 1

Contacts and locations

Locations

Johns Hopkins University School of Medicine

Baltimore, California, 21218, United States
Stanford University

Redwood City, California, 94063, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.